The National Anti-Doping Agency of India (INADA) has reported an anti-doping rule violation against the Athlete after her A and B samples tested positive for the prohibited substance stanozolol.
After notification INADA did not order a suspension but the Athlete voluntarily accepted a provisional suspension.
The Athlete stated she had used prescribed medication as treatment for a knee injury.
The Anti-Doping Disciplinary Panel of India (ADDPI) concluded there were grounds to annul or to reduce the period of ineligibility. On 17 January 2011 the ADDPI decided not to impose a period of ineligibility on the Athlete.
WADA appealed the ADDPI decision with the Anti-Doping Appeal Panel of India (ADAPI). A parallel WADA appeal with the Court of Arbitration for Sport (CAS) was withdrawn.
The Appeal Panel finds that the Athlete committed an anti-doping rule violation due to she failed to obtain a TUE and failed to mention the medical treatment on the Doping Control Form. The Athlete also failed to research the ingredients of the medication before using it.
Considering the circumstances the Appeal Panel concludes that the Athlete has not established that she exercised utmost caution and therefore she does not bear 'no fault or negligence'.
Therefore the Anti-Doping Appeal Panel of India rules to set aside the ADDPI decision and decides to impose a 2 year period of ineligibility on the Athlete starting on the date of the sample collection, i.e. on 16 May 2010.
